Daiichi Sankyo, Merck collaborate to develop and commercialize three Daiichi Sankyo DXd ADCs
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Subscribe To Our Newsletter & Stay Updated